Clinical trials: Rectal Cancer, Radiotherapy
Prostate Cancer (Post Prostatectomy), Anal Cancer
Assessment of New Radiation Oncology Technologies and Treatments
The Trans Tasman Radiation Oncology Group (TROG) has been commissioned by the Department of Health and Ageing to undertake a project to assess new Radiation Oncology Technology and Treatments.
- Conditions
- Prostate Cancer (Post Prostatectomy), Anal Cancer, Nasopharyngeal Cancer, Intermediate Risk Prostate Cancer
- Trial name
- ANROTAT (NCT01379872)
- Testing
- Non-Interventional Study
- Where
- 15 sites in Australia
- Volunteers
- 138 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Stage II Rectal Cancer, Organ Preservation
Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery
A randomized study of 131 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam…
- Conditions
- Stage II Rectal Cancer, Organ Preservation, Non-operative Treatment, Rectal Cancer (Stage III)
- Trial name
- MORPHEUS (NCT03051464)
- Testing
- Complete responders and Non-complete responders, Chemoradiation + EBRT Boost, Chemoradiation + HDRBT Boost
- Where
- 4 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Rectal Cancer, Adenocarcinoma
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
This is a single-center, exploratory clinical study for patients with newly diagnosed, high-risk, locally advanced rectal cancer.
- Trial name
- NCT07474103
- Testing
- SCRT, Liposomal Irinotecan, Oxaliplatin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated…
- Conditions
- HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT05639972
- Testing
- E7 TCR-T cells, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Christian Hinrichs
Anus Neoplasms, Carcinoma, Squamous Cell
Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients
The purpose of this study is to determine whether the combination of paclitaxel, capecitabine, mitomycin and intensity-modulated radiotherapy is more effective than the standard combination of capecitabine, mitomycin and…
- Conditions
- Anus Neoplasms, Carcinoma, Squamous Cell, Anus Diseases, Neoplasms
- Trial name
- NCT02526953
- Testing
- Paclitaxel, Capecitabine, Mitomycins
- Volunteers
- 314 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Malignant Neoplasm, Malignant Neoplasm of Rectum
Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial
The investigators hypothesize that an increase in dietary fiber intake during radiation therapy may provide better long-term intestinal health for the cancer survivor.
- Conditions
- Malignant Neoplasm, Malignant Neoplasm of Rectum, Malignant Neoplasm of Anus, Malignant Neoplasm of Urinary Bladder
- Trial name
- FIDURA (NCT04534075)
- Where
- Sweden
- Volunteers
- 354 people
- Sponsor
- Sahlgrenska University Hospital
Rectal Neoplasms
Adjuvant Treatment of Concurrent RT and CAPOX or Capecitabine Alone for Stage II and III Rectal Cancer
The purpose of this study is: To compare the long-term of survival and local/regional control between the two postoperative concurrent chemoradiotherapy regimens: capecitabine vs.
- Trial name
- NCT00714077
- Where
- 2 sites in China
- Volunteers
- 570 people
- Sponsor
- Chinese Academy of Medical Sciences
Locally Advanced Cancer in the Anal Region
Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0
To establish maximum tolerated dose of the two cytotoxic drugs 5-fluoruracil and mitomycin C when given together with the antibody cetuximab in patients with locally advanced cancer in the anal region To evaluate acute toxicity…
- Trial name
- NOAC8 (NCT01621217)
- Testing
- Cetuximab, Mitomycin C, 5-Fluoruracil
- Where
- 3 sites in Norway, Sweden
- Volunteers
- 21 people
- Sponsor
- Lund University Hospital
Locally Advanced Rectal Cancer, Locally Recurrent Rectal Cancer
Intraoperative Electron Radiotherapy in Rectal Cancer - A Feasibility Trial
Single centre double-blinded three-arm randomised controlled trial of extended margin surgery + IOERT at standard dose (10 Gy) versus extended margin surgery + IOERT at higher dose (15 Gy) versus extended margin surgery alone in…
- Trial name
- ELECTRA (NCT05877352)
- Testing
- Intraoperative Electron Radiotherapy (IOERT), Extended Margin Surgery
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Rectal Cancer
A Phase II Study of Oxaliplatin Capecitabine and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer
To assess the efficacy and safety of pre-operative capecitabine and oxaliplatin followed by capecitabine with concurrent radiotherapy followed by post-operative capecitabine in the treatment of patients with locally advanced or…
- Trial name
- NCT00220051
- Testing
- Oxaliplatin, Capecitabine, Pre operative radiotherapy, Surgical Resection
- Volunteers
- 109 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Rectal Neoplasms Malignant
CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer
Research objective: To compare the efficacy and safety of Capox + Bev versus Capox + Bev combined with primary site radiotherapy + (Iparomlimab and Tuvonralimab) as the first-line treatment for RAS Mutation/pMMR metastatic rectal…
- Trial name
- NCT07383285
- Testing
- Iparomlimab and Tuvonralimab, Radiotherapy to the primary site, Capecitabine
- Volunteers
- 106 people
- Sponsor
- Peking University Cancer Hospital & Institute
Pelvic Cancer, Anal Cancer
Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With HPV-positive Pelvic Cancer: a Descriptive Longitudinal Study
In patients with cancer associated with human papillomavirus (HPV), the physical effects of treatment, combined with the psychosexual impact linked to HPV status, can further impair the quality of sexual life.
- Conditions
- Pelvic Cancer, Anal Cancer, Vaginal Cancer
- Trial name
- SAPPHIRE (NCT07523152)
- Testing
- Assessment of sexual quality of life
- Volunteers
- 42 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Anal Cancer
Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer
The purpose of this study is to evaluate the efficacy and adverse events of intensity modulated radiation therapy (IMRT) concurrent with chemotherapy for anal squamous carcinoma.
- Trial name
- NCT03381352
- Testing
- Chemo-radiotherapy with IMRT technique, Capecitabine, Mitomycin C
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Chinese Academy of Medical Sciences
Rectal Neoplasms
Oxaliplatin in Rectal Cancer
Phase I: To determine the maximum tolerated dose, and recommended dose of the proposed doses of oxaliplatin in this study Phase II: To determine the treatment efficacy according to response rates from phase I.
- Trial name
- NCT00259363
- Testing
- Oxaliplatin
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- Sanofi
Rectal Cancer
Short Course Radiation Therapy Followed by Pre-operative Chemotherapy and Surgery in High-risk Rectal Cancer
Patients with a primary rectal cancer without detectable distant metastasis who after locoregional therapy only, meaning preoperative radio(chemo)therapy plus surgery have at least a 40% risk of not having a CRM negative…
- Trial name
- LARCT-US (NCT03729687)
- Testing
- radiotherapy, capecitabine, oxaliplatin
- Where
- Sweden
- Volunteers
- 280 people
- Sponsor
- Uppsala University
Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer
This study is a single-arm, prospective, phase II clinical study to evaluate the efficacy and safety of preoperative short-course radiotherapy combined with ivonescimab and chemotherapy + total mesorectal excision(TME) surgery in…
- Trial name
- NCT06760520
- Testing
- Ivonescimab (SMT112 or AK112) Injection
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Rectal Adenocarcinoma
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
This study is a prospective, open-label, phase I design.
- Trial name
- NCT04808323
- Testing
- Capecitabine, Initial Dose of Radiation before Dose Escalation, Cohort A: Dose Escalation Radiation
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Medical College of Wisconsin
Colorectal Cancer
Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma
This study is designed primarily to establish efficacy and estimate resource utilization. The short-term hypothesis is that the dose of capecitabine (825 mg/m2 twice/day 5 days per week) during the course of radiation therapy is…
- Trial name
- NCT00216424
- Testing
- Capecitabine (Xeloda)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- James A. Haley Veterans Administration Hospital
Recurrent Cancer, Prostate Cancer
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
This study investiagates deep-regional or superficial hyperthermia to enhance radiotherapy or chemoradiation in patients that suffer recurrent disease after previous radiotherapy.
- Conditions
- Recurrent Cancer, Prostate Cancer, Cervical Cancer, Anal Cancer
- Trial name
- HETERERO (NCT04889742)
- Testing
- loco-regional hyperthermia
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- Charite University, Berlin, Germany
Locally Advanced Rectal Cancer
SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer
The purpose of this research study is to find out how safe and effective is treating patients with locally advanced rectal cancer (LARC) with chemotherapy first and then follow with radiation therapy to a higher dose than what is…
- Trial name
- SMART TNT (NCT05412082)
- Testing
- Intensity-modulated radiation therapy, 5-fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Miami